Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionEssex Financial Services, Inc.
Latest Disclosed Ownership765 shares
Latest Disclosed Value $ 591,446
Essex Financial Services, Inc. reports 11.68% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 24, 2026 - Essex Financial Services, Inc. filed a 13F-HR form disclosing ownership of 765 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $591,446 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 685 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 11.68% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 765 80 11.68 591 11.93 0.0332
2026-02-10 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 685 109 18.92 529 63.47 0.0301
2025-11-07 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 576 576 324 0.0194
2025-07-16 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -410 -100.00 0 -100.00
2025-04-25 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 410 78 23.49 260 10.17 0.0187
2025-01-29 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 332 29 9.57 237 -18.90 0.0167
2024-10-24 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 303 -40 -11.66 292 -23.62 0.0210
2024-08-09 2024-06-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 343 83 31.92 382 52.40 0.0283
2024-07-31 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 273 13 287 0.0213
2024-04-24 2024-03-31 13F REGENERON PHARMACEUTICALS Stock 75886F107 260 260 250 0.0231
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.